RxDoctor Payments Data

Alexander Shtilbans, MD

Neurology · New York, NYNPI 1982871612

Payments from drug & device makers

$409,394in general payments, 2019–2025

Across 665 payments — averaging $615.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kyowa Kirin, Inc.$128K
  • Teva Pharmaceuticals USA, Inc.$75K
  • MDD US Operations, LLC$61K
  • Amneal Pharmaceuticals LLC$50K
  • UCB SA$36K
  • Acorda Therapeutics, Inc$29K
  • plus $31K from 15 others

What the payments were for

  • Consulting fees$24,1756%
  • Speaking & faculty fees$320,02586%
  • Travel & lodging$12,2373%
  • Food & beverage$15,9494%
  • Education$1,2400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$409,394 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$582,190
Medicare patients
377
Services billed
28,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate97$515,655
RytaryCarbidopa/Levodopa395$441,977
NourianzIstradefylline102$359,167
Radicava OrsEdaravone12$154,109
NeuproRotigotine105$115,971
IngrezzaValbenazine Tosylate14$106,689
GocovriAmantadine Hcl25$63,623
OngentysOpicapone56$37,333
LinzessLinaclotide42$24,708
Carbidopa-LevodopaCarbidopa/Levodopa883$23,118
InbrijaLevodopa11$22,985
CrexontCarbidopa/Levodopa25$18,254
Rasagiline Mesylate123$17,362
Carbidopa-Levodopa ErCarbidopa/Levodopa463$16,218
Selegiline Hcl172$13,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$5,668$515,65597 claims
Amneal Pharmaceuticals LLCRytary, Crexont$49,747$460,231420 claims
Kyowa Kirin, Inc.Nourianz$128,452$359,167102 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$7,994$144,02270 claims
UCB, Inc.Neupro$15,745$115,971105 claims
MDD US Operations, LLCGocovri$60,529$63,62325 claims
AbbVieLinzess$507$24,70842 claims
Acorda Therapeutics, IncInbrija$28,814$22,98511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →